Vedanta Biosciences Presents New Data from Phase 1 Study of VE202, Its Rationally-Defined Consortium for the Treatment of Inflammatory Bowel Disease, at the International Human Microbiome Consortium Congress 2021 (IHMC)
CARB-X 5th Anniversary -- Highlights from the portfolio
Vedanta Biosciences to Present at the SVB Leerink Biopharma Private Company Connect Event
Vedanta Biosciences to Present at the 2021 Jefferies Virtual Microbiome-Based Therapeutics Summit
